"10.1371_journal.pone.0094106","plos one","2014-04-17T00:00:00Z","Bernhard B Singer; Lena Opp; Annina Heinrich; Frauke Schreiber; Ramona Binding-Liermann; Luis Carlos Berrocal-Almanza; Kerstin A Heyl; Mario M Müller; Andreas Weimann; Janine Zweigner; Hortense Slevogt","Institute of Anatomy, University Hospital, University Duisburg-Essen, Essen, Germany; Institute of Microbiology and Hygiene, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; ZIK Septomics, University Hospital Jena, Jena, Germany; Labor Berlin - Charité Vivantes Services GmbH, Berlin, Germany; Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry of the Charité Universitätsmedizin Berlin, Berlin, Germany; Institute of Hygiene and Environmental Medicine, Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany","Conceived and designed the experiments: HS BBS. Performed the experiments: BBS LO MMM FS RBL KH AH. Analyzed the data: HS LCBA. Contributed reagents/materials/analysis tools: AW JZ. Wrote the manuscript: HS. Designed the study: HS.","BBS has rights to a patent application related to CEACAMs. HS is a PLOS ONE Editorial Board member. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors. The patent name and numbers is the following: BBS: Use of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis. United States Patent 8,501,192 and European Patent Application No. 07117396.7-2123.","2014","04","Bernhard B Singer","BBS",11,TRUE,2,7,2,1,TRUE,FALSE,FALSE,0,NA,FALSE
